NewKerala.com

Lupin Acquires VISUfarma to Expand European Eye Care Portfolio

Lupin Ltd. has finalized its acquisition of European ophthalmology-focused company VISUfarma B.V. The deal significantly expands Lupin's eye care portfolio to over 60 branded products across various conditions. The acquisition strengthens Lupin's commercial footprint in key European markets like Italy, the UK, and Germany. Company leadership states the move supports addressing growing global demand driven by an aging population and diabetes-related eye complications.

Key Points: Lupin Completes VISUfarma Acquisition for European Growth

  • Expands ophthalmology portfolio to 60+ products
  • Strengthens presence in key European markets
  • Addresses growing global demand for eye care
  • Acquisition is immediately accretive to business
2 min read

Lupin completes acquisition of VISUfarma to boost European eye care portfolio

Lupin Ltd. completes acquisition of VISUfarma, boosting its ophthalmology portfolio to over 60 products and strengthening its European presence.

"The VISUfarma acquisition marks a very exciting milestone for Lupin - Vinita Gupta"

New Delhi, April 2

Lupin Ltd. has completed the acquisition of VISUfarma B.V, a European pharmaceutical company focused on ophthalmology, the company said in an exchange filing on Thursday. Lupin said the acquisition is a "significant milestone" in its strategy to expand the speciality care portfolio and strengthen its presence in the European region.

"The integration of VISUfarma has significantly expanded Lupin's ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals," the company said in the release.

The acquisition is expected to benefit Lupin as VISUfarma has a strong presence across key European market, including Italy, UK, Spain, Germany, and France. The acquired company's teams in these regions are equipped with deep ophthalmology expertise, trusted relationships, and strong local market insight.

The company said VISUfarma will support its ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the growing burden of diabetes-related eye complications.

Vinita Gupta, Chief Executive Officer of the company noted, "The VISUfarma acquisition marks a very exciting milestone for Lupin, adding a differentiated portfolio of more than 60 innovative eye health products supported by an established commercial infrastructure. Beyond being immediately accretive, this strategic acquisition will also expand our presence across Europe and accelerate the build-out of our speciality franchise."

Paolo Ciocetti, the chief executive officer of VISUFarma (Italy), said they are "thrilled" to begin the next chapter with Lupin as they see the Indian pharma major as an ideal partner due to its global expertise and commitment to Ophthalmology. "Together, we are confident that we can make a significant impact in advancing eye care across Europe and beyond," Ciocetti added.

Lupin Limited is an Indian pharmaceutical company with its headquarters in Mumbai and its products distributed in over 100 markets.

At the time of filing this report, Lupin Ltd was trading at Rs 2254.60 per share, down 0.89 per cent, on the National Stock Exchange.

- ANI

Share this article:

Reader Comments

P
Priya S
Very proud moment. Lupin acquiring a European company with such a strong portfolio is a testament to the quality and ambition of our homegrown firms. Hope this leads to more affordable eye care solutions being developed for the Indian market as well.
V
Vikram M
Smart acquisition. The European market is tough to crack, and buying an established player with local teams is the right way to do it. The share price dip is just noise, long-term this will be very beneficial for Lupin's revenue diversification.
S
Sarah B
As someone who follows the pharma sector, this is a significant deal. Lupin is moving beyond generics into branded specialty care, which has better margins. The ophthalmology focus addresses a clear global need. Well done to the management team.
R
Rohit P
Good news, but I hope Lupin doesn't lose focus on the domestic market. We have a huge burden of diabetes and related eye problems here in India. The expertise from VISUfarma should be leveraged to develop cost-effective solutions for Indian patients too.
M
Michael C
Impressive to see an Indian company being seen as an "ideal partner" by a European firm. Speaks volumes about the reputation Lupin has built globally. The integration will be key – hope they retain the local expertise and relationships VISUfarma has.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50